News
ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2021. The financial results will be reported in a press release...
ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®
H&H Group expands Swisse® healthy aging product line into growing NAD+ space with Niagen® from ChromaDex LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group,...
ChromaDex Appoints Fadi Karam as Chief Marketing Officer
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. Karam has spent his career driving consumer businesses across multiple geographies and cultures, including scaling direct-to-consumer operations...
ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency
ChromaDex External Research Program (CERP) and the Citrin Foundation to collaborate on series of studies exploring rare disease citrullinemia LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore...
ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Lytham Partners Spring 2021 Investor Conference. The ChromaDex management team is...
ChromaDex to Present at the Zooming with LD Virtual Investor Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor conference. The ChromaDex management team is scheduled to...
ChromaDex Corporation Reports 2020 Financial Results
Revenue for the Three-Month Period Ended December 31, 2020 Totals $15.4 Million, up 18% Year-over-Year, with Gross Margin of 61.0%, and Lower Operating Expenses. Full Year Revenue of $59.3 Million, with $47.1 Million from Tru Niagen®. LOS ANGELES - ChromaDex...
ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States
Industry-leading NAD+ booster and healthy aging nutrient Tru Niagen® will be available in 3,000 Walmart stores across the U.S. beginning in June 2021 LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product and industry-leading...
ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:50pm ET (12:50pm PT). A webcast of the presentation will be posted under the...
ChromaDex Appoints Preventative Medicine Specialist Dr. David L. Katz to its Scientific Advisory Board
Globally recognized authority on lifestyle medicine joins ChromaDex SAB to bolster company's healthy aging research efforts LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc,...